1-(5-硝基吡啶-2-基)哌啶-4-醇 | 353258-16-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 1-(5-硝基吡啶-2-基)哌啶-4-醇
• 英文名称: 1-(5-nitropyridin-2-yl)piperidin-4-ol
• 英文别名: 1-(5-Nitro-2-pyridinyl)-4-piperidinol
• CAS: 353258-16-9
• 化学式: C₁₀H₁₃N₃O₃
• mdl: MFCD01310144
• 分子量: 223.232
• InChiKey: JHDAKLOFMCIERS-UHFFFAOYSA-N

物化性质

• 沸点：
  441.0±45.0 °C(Predicted)
• 密度：
  1.363±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  82.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(5-硝基吡啶-2-基)哌啶-4-醇 在 Adam’s catalyst 、 氢气 、 四丁基碘化铵 、 sodium hydride 作用下， 以 四氢呋喃 、 乙酸乙酯 、 异丙醇 为溶剂， 生成 Methyl 3-((1-(5-aminopyridin-2-yl)piperidin-4-yloxy)methyl)benzoate
  参考文献：
  名称：

  领先的吡啶-羧酰胺系列作为DGAT-1抑制剂的优化

  摘要：

  描述了一系列新型的吡啶甲酰胺类羧酸衍生物作为DGAT-1抑制剂的构效关系。基于体外和体内活性的初始铅化合物6的优化导致关键化合物10j和17h的发现。

  DOI：

  10.1016/j.bmcl.2012.12.040
• 作为产物：
  描述：

  4-苯基-4-羟基哌啶 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 生成 1-(5-硝基吡啶-2-基)哌啶-4-醇
  参考文献：
  名称：

  INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

  摘要：

  本发明涉及作为二酰基甘油酰基转移酶（“DGAT”）抑制剂的新型杂环化合物，包括所述杂环化合物的药物组合物以及利用这些化合物治疗或预防心血管疾病、代谢紊乱、肥胖或与肥胖相关的疾病、糖尿病、血脂异常、糖尿病并发症、糖耐量受损或空腹血糖受损的用途。本发明的一种示例化合物如下所示：式（I）。

  公开号：

  US20110224137A1

文献信息

• [EN] GLUTAMINASE INHIBITORS<br/>[FR] INHIBITEURS DE GLUTAMINASE
  申请人：UNIV PITTSBURGH

  公开号：WO2016054388A1

  公开（公告）日：2016-04-07

  A compound, or a pharmaceutically acceptable salt thereof, having a structure of: Formula A wherein A is a ring; Y1 and Y2 are each independently N or C with the proper valency; X1 and X2 are each independently -NH-, -0-, -CH2-0-, -NH-CH2-, or -N(CH3)-CH2-, provided that when at least one of X1 and X2 is -CH2-0-, -NH-CH2-, or -N(CH3)-CH2- then the - CH2- is directly connected to A; a and b are each independently 0 or 1; c and d are each independently 0 or 1; Z1 and Z2 are each independently a heterocyclic; and R1 and R2 are each independently optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, amino, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; provided that if Y1 and Y2 are each C, then a is 1 and b is 1; provided that if Y1 and Y2 are each N, then a is 0 and b is 0; provided that if Y1 is N and Y2 is C, then a=0 and b=l; provided that if Y1 is C and Y2 is N, then a=l and b=0; provided that if c=0 and d=0, then R1 and R2 are both amino; provided that if c is 1 and d is 1, then both R1 and R2 are not amino; provided that if c is 0 and d is 1, then R1 is amino and R2 is optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl; and provided that if c is 1 and d is 0, then R2 is amino and R1 is optionally substituted alkyl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroaralkyl, optionally substituted alkylalkoxy, optionally substituted alkylaryloxy, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocycloalkyl.

  一种化合物，或其药学上可接受的盐，其结构如下：公式A，其中A是一个环；Y1和Y2分别独立地是N或C，具有适当的价；X1和X2分别独立地是-NH-、-O-、-CH2-O-、-NH-CH2-或-N(CH3)-CH2-，但是当X1和X2中至少有一个是-CH2-O-、-NH-CH2-或-N(CH3)-CH2-时，那么-CH2-直接连接到A；a和b分别独立地是0或1；c和d分别独立地是0或1；Z1和Z2分别独立地是一个杂环；R1和R2分别独立地是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、氨基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基；但是如果Y1和Y2分别是C，则a为1且b为1；如果Y1和Y2分别是N，则a为0且b为0；如果Y1是N且Y2是C，则a=0且b=1；如果Y1是C且Y2是N，则a=1且b=0；如果c=0且d=0，则R1和R2都是氨基；如果c为1且d为1，则R1和R2都不是氨基；如果c为0且d为1，则R1是氨基且R2是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基；如果c为1且d为0，则R2是氨基且R1是可选择地取代的烷基、可选择地取代的芳基烷基、可选择地取代的环烷基、可选择地取代的杂芳基烷基、可选择地取代的烷基氧基、可选择地取代的烷基芳基氧基、可选择地取代的芳基、可选择地取代的杂芳基、或可选择地取代的杂环烷基。
• [EN] AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR-1 D'HORMONE DE MÉLANO-CONCENTRATION D'AZOLOTRIAZINONE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010042682A1

  公开（公告）日：2010-04-15

  The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I, wherein R1, is selected from the group consisting of monocyclic aryl or monocyclic heteroaryl; W is selected from the group consisting of a direct bond, -O-, and -N(R6)-; provided that if W is a direct bond, D is a cyclic amine that is attached to A via the nitrogen atom of the cyclic amine; D is selected from the group consisting of a direct bond, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, cycloalkylalkyl, and 4- to 6-membered cyclic amines, provided that if D is a direct bond, R2a, R2b, and R2c must be selected from H, alkyl, or cycloalkyl; E and G are independently N or CH provided that both are not N; R1 is substituted or unsubstituted phenyl or substituted or unsubstituted monocyclic heteroaryl; R2a, R2b, and R2c are independently selected from the group consisting of hydrogen, halo, cyano, hydroxyl, -NR5R5a, -SO2R34, -CO2R35 -NR5CO2R21, -NR5COR21, substituted or unsubstituted C1 to C4 alkyl, substituted or unsubstituted C3 to C7 cycloalkyl, substituted or unsubstituted 4- to 6-membered cyclic amines wherein said cyclic amine is optionally substituted with -OH, carbonylamino, alkoxycarbonylamino, or at least one of R2a, R2b, and R2c is a prodrug moiety selected from amino acid esters or phosphoric acid esters wherein said amino acid ester has the formula -OC(O)CH(NH2)R31, wherein R31 is H or C1 to C4 alkyl; or any two of R2a, Rb, or R2c, may be taken together to form a ring; R3 and R3a are each independently selected from the group consisting of hydrogen, hydroxyl, lower alkoxy, halo, CN, substituted or unsubstituted C1 to C4 alkyl, perfluoroalkyl, substituted or unsubstituted C3 to C7 cycloalkyl, cycloalkoxy, amino, alkylamino, dialkylamino, and aminoalkyl, wherein R3 or R3a and D may optionally be taken together with the atoms to which they are attached to form a 5- to 7-membered ring; R5 and R5a are the same or different and are independently selected from the group consisting of hydrogen, substituted or unsubstituted lower alkyl, hydroxyalkyl, hydroxyalkylcycloalkyl, substituted or unsubstituted heterocycloalkyl, acyl, alkoxycarbonyl, carboxyalkyl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted cycloalkylalkyl, wherein the R5 and R5a groups and the N atom to which they are attached may form a ring; R21 and R31 are each H or C1 to C4 alkyl; R34 is alkyl; R35 is H or alkyl; and R6 is selected from the group consisting of H, C1 to C4 alkyl and C3 to C7 cycloalkyl.

  本申请提供了作为MCHR1拮抗剂有用的化合物，特别用于肥胖症的治疗，包括所有立体异构体、溶剂化合物、前药和根据式I的药学上可接受的形式，其中R1从单环芳基或单环杂芳基组成的群体中选择；W从直接键、-O-和-N(R6)-组成的群体中选择；条件是如果W是直接键，则D是通过环胺的氮原子连接到A的环胺；D从直接键、取代或未取代的C1到C4烷基、取代或未取代的C3到C7环烷基、环烷基烷基和4-到6-成员环胺组成的群体中选择，条件是如果D是直接键，则R2a、R2b和R2c必须从H、烷基或环烷基中选择；E和G独立地是N或CH，条件是两者都不是N；R1是取代或未取代的苯基或取代或未取代的单环杂芳基；R2a、R2b和R2c独立地从氢、卤素、氰基、羟基、-NR5R5a、-SO2R34、-CO2R35 -NR5CO2R21、-NR5COR21、取代或未取代的C1到C4烷基、取代或未取代的C3到C7环烷基、取代或未取代的4-到6-成员环胺中选择，其中所述环胺可以选择地取代为-OH、羰基氨基、烷氧羰基氨基，或R2a、R2b和R2c中的至少一个是选择自氨基酸酯或磷酸酯的前药基团，其中所述氨基酸酯具有式-OC(O)CH(NH2)R31，其中R31为H或C1到C4烷基；或R2a、Rb或R2c中的任意两个可以结合形成环；R3和R3a各自独立地从氢、羟基、较低烷氧基、卤素、CN、取代或未取代的C1到C4烷基、全氟烷基、取代或未取代的C3到C7环烷基、环烷氧基、氨基、烷基氨基、二烷基氨基和氨基烷基中选择，其中R3或R3a和D可以选择地结合形成5-到7-成员环；R5和R5a相同或不同，独立地从氢、取代或未取代的较低烷基、羟基烷基、羟基烷基环烷基、取代或未取代的杂环烷基、酰基、烷氧羰基、羧基烷基、取代或未取代的环烷基和取代或未取代的环烷基烷基中选择，其中R5和R5a基团和它们连接的N原子可以形成环；R21和R31各自为H或C1到C4烷基；R34为烷基；R35为H或烷基；R6从H、C1到C4烷基和C3到C7环烷基中选择。
• [EN] NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES AZOTÉS ET LEUR APPLICATION DANS DES MÉDICAMENTS
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015090232A1

  公开（公告）日：2015-06-25

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法以及作为药物的用途，特别是用于治疗和预防组织纤维化。本文还提供了包含这些含氮杂环化合物的药用可接受组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、IPF、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• [EN] INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION PAR WNT/Beta-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2013040215A1

  公开（公告）日：2013-03-21

  lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本文披露了用于治疗各种疾病和病理的吲唑-3-羧酰胺化合物。更具体地，本文涉及使用吲唑-3-羧酰胺化合物或其类似物治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或Wnt信号组分之一或多个的突变或失调而引起的遗传疾病和神经系统疾病/紊乱/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• [EN] METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] PROCÉDÉS D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2018075858A1

  公开（公告）日：2018-04-26

  This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

  本公开涉及使用一种或多种吲唑-3-羧酰胺化合物或其盐或类似物，用于治疗独立选择自包括肌腱病、皮炎、牛皮癣、硬皮病、鱼鳞病、雷诺综合征和达里尔病的一种或多种疾病或症状；和/或促进伤口愈合。方法包括向受试者（例如，需要者）施用如本文中任何地方所述的一种或多种吲唑-3-羧酰胺化合物或其盐或类似物的治疗有效量。